These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11926874)

  • 61. Human leukocyte antigen-associated drug hypersensitivity.
    Illing PT; Vivian JP; Purcell AW; Rossjohn J; McCluskey J
    Curr Opin Immunol; 2013 Feb; 25(1):81-9. PubMed ID: 23141566
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
    Gatanaga H; Yazaki H; Tanuma J; Honda M; Genka I; Teruya K; Tachikawa N; Kikuchi Y; Oka S
    AIDS; 2007 Jan; 21(2):264-5. PubMed ID: 17197830
    [No Abstract]   [Full Text] [Related]  

  • 63. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 64. Preliminary report on 1592.
    AIDS Clin Care; 1997 Sep; 9(9):71. PubMed ID: 11364756
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
    Hu K; Xiang Q; Wang Z; Mu GY; Zhang Z; Ma LY; Xie QF; Chen SQ; Zhou S; Zhang XD; Cui YM
    BMC Infect Dis; 2019 Jul; 19(1):583. PubMed ID: 31277607
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacogenetic information derived from analysis of HLA alleles.
    Gatanaga H; Honda H; Oka S
    Pharmacogenomics; 2008 Feb; 9(2):207-14. PubMed ID: 18370849
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genetic testing may avoid abacavir hypersensitivity reaction.
    James JS
    AIDS Treat News; 2006; (419):6-7. PubMed ID: 17096489
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 69. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

  • 71. Complications and side effects. Abacavir hypersensitivity testing results--Montreal.
    TreatmentUpdate; 2007; 19(5):8-9. PubMed ID: 17955617
    [No Abstract]   [Full Text] [Related]  

  • 72. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction.
    Escaut L; Liotier JY; Albengres E; Cheminot N; Vittecoq D
    AIDS; 1999 Jul; 13(11):1419-20. PubMed ID: 10449301
    [No Abstract]   [Full Text] [Related]  

  • 73. Hypersensitivity syndrome associated with efavirenz therapy.
    Bossi P; Colin D; Bricaire F; Caumes E
    Clin Infect Dis; 2000 Jan; 30(1):227-8. PubMed ID: 10619772
    [No Abstract]   [Full Text] [Related]  

  • 74. Agranulocytosis induced by abacavir.
    Tikhomirov V; Namek K; Hindes R
    AIDS; 1999 Jul; 13(11):1420-1. PubMed ID: 10449302
    [No Abstract]   [Full Text] [Related]  

  • 75. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Neuropsychiatric reaction induced by abacavir.
    Colebunders R; Hilbrands R; De Roo A; Pelgrom J
    Am J Med; 2002 Nov; 113(7):616. PubMed ID: 12459415
    [No Abstract]   [Full Text] [Related]  

  • 77. How do abacavir and efavirenz differ in pharmacokinetics and toxicity?
    Edmunds-Ogbuokiri J
    Fac Notes (New Orleans La); 1999; 11(3):1-4. PubMed ID: 11810867
    [No Abstract]   [Full Text] [Related]  

  • 78. Chronic cough induced by abacavir apart from a context of hypersensitivity.
    Peyrière H; Mauboussin JM; Arnaud A; Rouanet I; Vincent D
    Allerg Immunol (Paris); 2002 Dec; 34(10):359-60. PubMed ID: 12575618
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Safety in routine clinical practice. Hypersensitivity can be managed].
    MMW Fortschr Med; 2000; 142(3 Suppl):22-3. PubMed ID: 10893956
    [No Abstract]   [Full Text] [Related]  

  • 80. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
    García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
    AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.